|Bid||200.12 x 800|
|Ask||200.26 x 800|
|Day's range||198.83 - 202.94|
|52-week range||185.33 - 283.45|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||19.08|
|Earnings date||29 July 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||260.91|
BOSTON, July 28, 2021--Vertex announces initiation of Phase 3 development program for new once-daily triple combination of VX-121/tezacaftor/VX-561 (deutivacaftor).
Market crashes and steep corrections are the perfect opportunity to buy high-quality stocks at a discount.
On Vertex's (VRTX) second-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and pipeline progress.